Personal NO2 and volatile organic compounds exposure levels are associated with markers of cardiovascular risk in women in the Cape Town region of South Africa by Everson, Frans et al.




Personal NO2 and Volatile Organic Compounds
Exposure Levels are Associated with Markers of
Cardiovascular Risk in Women in the Cape Town
Region of South Africa
Frans Everson 1 , Patrick De Boever 2,3,* , Tim S. Nawrot 3, Nandu Goswami 4,
Mashudu Mthethwa 1, Ingrid Webster 1, Dries S. Martens 3, Nyiko Mashele 1, Sana Charania 1,
Festus Kamau 1 and Hans Strijdom 1
1 Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University,
P.O. Box 241, Cape Town 8000, South Africa
2 Health Unit, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium
3 Centre for Environmental Sciences, Hasselt University, 3590 Diepenbeek, Belgium
4 Division of Physiology, Otto Loewi Research Center of Vascular Biology, Immunity and Inflammation,
Medical University of Graz, 8036 Graz, Austria
* Correspondence: patrick.deboever@vito.be; Tel.: +32-14-335145
Received: 18 May 2019; Accepted: 15 June 2019; Published: 28 June 2019


Abstract: Exposure to ambient NO2 and benzene, toluene ethyl-benzene and m+p- and o-xylenes
(BTEX) is associated with adverse cardiovascular effects, but limited information is available on
the effects of personal exposure to these compounds in South African populations. This 6-month
follow-up study aims to determine 7-day personal ambient NO2 and BTEX exposure levels via
compact passive diffusion samplers in female participants from Cape Town, and investigate whether
exposure levels are associated with cardiovascular risk markers. Overall, the measured air pollutant
exposure levels were lower compared to international standards. NO2 was positively associated with
systolic and diastolic blood pressure (SBP and DBP), and inversely associated with the central retinal
venular equivalent (CRVE) and mean baseline brachial artery diameter. o-xylene was associated
with DBP and benzene was strongly associated with carotid intima media thickness (cIMT). Our
findings showed that personal air pollution exposure, even at relatively low levels, was associated
with several markers of cardiovascular risk in women residing in the Cape Town region.
Keywords: air pollution; nitrogen dioxide; BTEX; cardiovascular risk; South Africa
1. Introduction
Ambient air pollution is a global health concern and is associated with numerous adverse health
effects including cardiovascular disease (CVD) [1–3]. The health effects of ambient air pollution
are mostly attributable to small particles and chemically reactive compounds with pro-oxidative
potential [4–7]. Previous reports have suggested that the adverse cardiovascular effects associated
with air pollution exposure may be due to autonomic nervous system dysregulation of vascular
tone and heart rates [8,9], and pro-atherosclerotic processes such as oxidative stress, inflammation,
and endothelial dysfunction [9–11]. Although several chemical components present in ambient
air have been implicated in adverse cardiovascular outcomes (e.g., nitrogen and carbon oxides,
and particulate matter (PM)), the specific contributions and underlying mechanisms of exposure to
individual components are not well understood [1,12,13].
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The World Health Organization (WHO) has identified gaseous pollutants such as NO2 and
PM with a diameter of ≤2.5 µm (PM2.5) as the air pollutants that are most dangerous to public
health [14]. Other gaseous pollutants in ambient air include polycyclic aromatic hydrocarbons (PAHs)
such as benzene, toluene ethyl-benzene and m+p- and o-xylenes (BTEX) [15–18]. These gaseous
pollutions are mostly produced as a result of the incomplete combustion of fossil fuels during industrial,
vehicle, and household activities and are therefore considered a good proxy for general air quality
and combustion-related emissions [15–18]. Due to their small molecular size (molecular diameter:
<0.1 nm), these ambient air pollutants are able to passively enter the blood circulation during respiration
(predominant route of exposure) and disseminate throughout the body, even at the cellular and nuclear
levels where they can exert their harmful effects [1,7,19].
Reports on air pollution levels and related health effects are mostly based on data from the
developed world, while the situation in developing countries remains under-reported [20–23]. A
recently published systematic review by Katoto et al. (2019) highlighted the lack of air pollution data
from the sub-Saharan Africa (SSA) region [23]. The authors identified only 23 published research
articles from SSA (of which 14 were from South Africa) that reported on the health effects associated
with ambient air pollution. It is evident, however, that data from personal quantitative exposure
measurements are under-reported, and none of these studies investigated the effects of air pollution
on vascular health and function. The review furthermore reported on studies demonstrating urban
air pollution levels of up to 10–20 times greater than recommended WHO standards in some SSA
locations [23]. In light of these findings and knowledge gaps, the overarching aims of the current study
were to: (1) determine current levels of personal NO2 and BTEX exposure during two 1-week time
periods in a repeated-measurements study (6-month follow-up) of apparently healthy women residing
in the Cape Town region of South Africa, and (2) determine whether current levels of personal NO2 and
BTEX exposure are associated with markers of cardiovascular risk, including blood pressure (systolic
blood pressure (SBP) and diastolic blood pressure (DBP), respectively), flow-mediated vasodilatation
(FMD), retinal blood vessel widths, and carotid intima media thickness (cIMT).
2. Materials and Methods
2.1. Study Ethics, Design, and Population
The current study formed part of a larger parent study called EndoAfrica and participants
for the current study were recruited from the healthy control study group of the parent study [24].
Ethical clearance for the current study was obtained from the Health Research Ethics Committee
of Stellenbosch University (ethics reference number: S16/07/114), which subscribes to the principles
of the Helsinki Declaration (1975). The study followed a non-interventional, longitudinal (6-month
follow-up) cohort design. Healthy volunteering female participants of mixed ancestry were randomLy
recruited for the first assessment visit (baseline) from September 2016 to August 2017 at primary
health care clinics in the Cape Town region. All participants were from the residential areas of Elsies
River, Bishop Lavis, and Ravensmead. All 6-month assessment visits (follow-up) were completed by
February 2018. Qualified research nurses recruited, screened, and obtained informed consent from all
participants. Participants who were <18 years of age, with human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS; confirmed with a rapid HIV test; SD Bioline HIV 1/2 3.0
immunochromatographic test kit; Standard Diagnostics, Republic of Korea), with current tuberculosis
(confirmed from participant clinic files), pregnant (confirmed with a pregnancy test), <3 months
post-partum, of poor health, or with a current or previous history of heart disease were excluded.
2.2. Air Quality and Temperature Monitoring
Each participant was equipped with a Gradko rapid NO2 device (Gradko International Ltd.,
Winchester, UK), a RadielloTM BTEX passive diffusion sampler (Sigma-Aldrich Inc., MO, USA), and
an ACR SmartButton® temperature logger (ACR Systems Inc., Surrey, B.C., Canada) placed in the
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external mesh pocket of a backpack (Figure A1a–d). The mesh pocket allowed for unrestricted
continuous contact with ambient indoor and outdoor temperature and air (Figure A1e). Although
previous studies have measured personal sampling within a 30 cm hemisphere from the face [25,26],
personal exposure for the current study was measured within a hemisphere of 50 to 60 cm from the
face (Figure A1f). Participants carried the backpack at all times (except during periods of sleep and
bathroom use when the backpack was placed next to their beds) for a 7-day period. Temperature was
recorded continuously at 30-minute intervals while the NO2 and BTEX samplers allowed for continuous
passive diffusion and accumulation of NO2 and BTEX. Following continuous 7-day measurements,
participants returned for the first assessment visit, during which the backpacks were collected, data
were extracted from the temperature loggers via ACR TrendReader® software (ACR Systems Inc.,
Surrey, B.C., Canada), and the average temperature (◦C) for the 7-day period was recorded. Once
collected, the NO2 and BTEX samplers were sealed, stored at 4 ◦C and sent for quantification according
to the manufacturer’s protocol.
NO2 samplers were sent to Gradko International Ltd. laboratories (United Kingdom Accreditation
Services (UKAS) accredited)) for quantification according to UKAS method GLM 7 [27]. A calibration
curve (blank with only deionized water, 15, 30, 60, 90 120 µg/mL) was prepared from a standard nitrate
solution (1 g/L nitrite ion (NO2−)). The color reagent was prepared as previously described [28] and
used in a sample:sulphanilamide solution:N-1 (naphthyl-1) ethylene diamine dihydrochloride solution
(NEDD) ratio of 1:2:2 (0.003 g NEDD per 1 g sulphanilamide). After sample elution (preparation:
20 % triethanolamine (TEA) solution/80% deionized water), NO2 concentrations were determined
via chemiluminescence ultraviolet (UV) spectrophotometry (UVS04 Camspec M550; Spectronic
Camspec Ltd., Leeds, UK). Calibration standards and linearity checks were used to calibrate the
spectrophotometer, and mid-range and zero standards were analyzed at intervals throughout the
sequence for quality assurance. The calibration curve was used to calculate the NO2- concentration for
each sample. The ambient NO2 concentration was calculated from NO2− concentrations and expressed
as µg/m3 [29].
BTEX samplers were sent to the Flemish Institute for Technology and Research (VITO; Mol,
Belgium) for quantification as previously described [30,31]. BTEX samples were extracted from
exposed samplers by means of elution in the RadielloTM glass tube containing the cartridge
(2 mL carbon disulphide (CS2; Sigma-Aldrich, MO, USA) and 12.5 µL 2-fluorotoluene internal
standard (Sigma-Aldrich, MO, USA)). The tube was stirred for 30 minutes on a rotational shaker.
BTEX quantification was performed by means of gas chromatography (Thermo Trace) and a mass
spectrometer (Thermo DSQ II with helium as carries gas (a constant flow of 1 mL/min)). A cross-bond
diphenyl/dimethylpolysiloxane column (RTX 502.2; 0.25 mm by 30 m) with a 1.4 µm-thick film was
used for sample separation (temperature program: 35 ◦C for 5 minutes, 14 ◦C/minute increment
until 245 ◦C). Equipment calibration was performed by injecting the standard solution (benzene,
ethyl-benzene, toluene, m-xylene, p-xylene, and o-xylene in CS2 (Sigma-Aldrich, MO, USA)) at 0.03 to
30 µg/g before analysis. Sample concentrations were calculated from chromatograms using a standard
curve. The limit of detection (LOD) was calculated as 3.3 (standard deviation (SD) of areas/slope).
Samples with conc. <LOD were not presented. Results were expressed as average NO2 and BTEX
exposure concentration (µg/m3) for the 7-day measuring period. The same procedure was followed for
the 6-month follow-up visits.
2.3. Study Endpoints
2.3.1. Health Questionnaire and Anthropometric Measurements
At each visit, participants completed a comprehensive questionnaire to collect data on age, smoking
status (defined as smoking or non-smoking), socioeconomic information (including employment status
defined as either unemployed, part-time employed, or full-time employed), and lifestyle (hours of sleep
at night defined as 1 to 3 hours, between 3 and 6 hours, 6 to 9 hours, and >9 hours). Qualified research
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nurses measured fasting blood glucose levels (mmol/L) by finger prick (Gluco PlusTM, Cipla DIBCARE,
Bellville, South Africa) and collected fasting blood and mid-stream urine samples. Cardiovascular
measurements included SBP and DBP (calculated as an average of 3 measurements at 5-minute intervals
on the left arm and expressed in mmHg) via an Omron M6 automatic digital blood pressure monitor
(Omron Healthcare, Kyoto, Japan). Hypertension was defined as either SBP of ≥140 mmHg or DBP of
≥90 mmHg, based on the South African Hypertension Society guidelines [32]. Body mass (kg) was
determined on an electronic scale, and height (cm) was decided by means of a stadiometer. Finally,
body-mass index (BMI) was expressed as kg body weight/m2 height.
2.3.2. Biochemical Analysis
Fasting whole blood was collected in blood collection tubes (SGVac, The Scientific Group (Pty)
Ltd.; Milnerton, Western Cape, SA). Serum was extracted from whole blood samples and stored at
−80 ◦C. Serum samples were analyzed by the South African National Health Laboratory Service
(NHLS; Tygerberg Hospital, Cape Town, South Africa), a South African National Accreditation System
(SANAS)-accredited laboratory, for high-sensitivity C-reactive protein (hsCRP) levels by means of
an IMMAGE® Immunochemistry Systems and Calibrator 5 Plus assay kit (Beckman Coulter, Inc.,
CA, USA). This specific chemiluminescence analysis was based on the highly sensitive Near Infrared
Particle Immunoassay rate methodology where anti-CRP antibody-coated particles bind to the CRP in
the serum sample resulting in an insoluble aggregate formation and turbidity. Samples were prepared
for analysis by adding 4.5 µL serum sample, 42 µL antibody-coated particles (particle-bound goat and
mouse anti-CRP antibody), 125 µL buffer 4 and 42 µL diluent (sodium azide: <0.1% (w/w)). The hsCRP
concentration was determined automatically as the rate of aggregate formation (directly proportional).
For the purposes of this study, increased hsCRP was defined as hsCRP levels of >3 mg/L based on
previous reports suggesting that hsCRP levels above this cut-off value are associated with increased
cardiovascular risk [33].
Mid-stream urine samples were obtained at each visit, placed on ice and immediately delivered to
the NHLS for the quantification of urinary creatinine levels by means of chemiluminescence (cobas®-c
analyzer and CREP2 kit; Roche Diagnostics, Basel, Switzerland). The principal of the method was
based on the enzymatic formation of hydrogen peroxide (catalyzed by peroxidase) that reacted with
2,4,6-triiodo-3-hydroxybenzoic acid for quinone imine chromogen. Creatinine levels were determined
by the color intensity of the quinone imine chromogen (directly proportional).
2.3.3. Urinary Analysis of Metabolites of Volatile Organic Compounds
Additional mid-stream urine samples were stored at −80 ◦C and sent to VITO (Mol, Belgium) for
level determinations of the following urinary metabolites: N-acetyl-S-(3-hydroxypropyl)-L-cysteine
(HPMA; a marker of acrolein exposure [34]), N-acetyl-s-(phenyl)-L-cysteine (PMA; a marker of
benzene exposure [35]), N-acetyl-s-(benzyl)-L-cysteine (BMA; a marker of toluene exposure [36]),
trans,trans-muconic acid (MU; a marker of benzene exposure [35]), and 3+4-methylhippuric acid
(3+4MHA; a marker of o-, m-, and p-xylene exposure [37]). Samples were prepared using 10 µL
urine, 25 µL mixed internal standard (2000 ng/mL in methanol:water(1:1, v:v)) MU-d4 and 3 (Santa
Cruz Biotechnology, TX, USA), and 4 MHA-d7 (Toronto research chemicals Inc., ON, Canada) with
465 µL 1% acetic acid (HAc; Merck, NJ, USA). A matrix-matched calibration curve was applied for
the quantification of HPMA, BMA, and PMA to compensate for the matrix effect. To achieve this,
spiked urine samples were used containing 10 µL urine, 25 µL mixed internal standard (MU-d4 and
2,3 and 4 MHA-d7: 2000 ng/mL, 20 µL low and high spiked standards (low spike: HPMA, 37.5 ng/mL;
PMA, 0.25 ng/mL; MU 5.0 ng/mL, BMA, 1.25 ng/mL; 3+4MHA, 20.0 ng/mL; and high spike: HPMA,
75.0 ng/mL PMA, 0.5 ng/mL; MU, 10.0 ng/mL; BMA, 2.5 ng/mL; 3+4MHA, 40.0 ng/mL (Toronto research
chemicals Inc., ON, Canada)) and 445 µL 1% HAc in ultra-pure water.
Twenty microliters of each sample was injected in an ultra-performance liquid chromatography
(UPLS; Waters I-class Acquity UPLC system, Milford, MA, USA)/mass spectrometry (MS; Waters Xevo
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TQ-S tandem in the negative electrospray ionization mode (ESI−)). An Acquity UPLC® high-strength
silica T3 column (50 mm × 2.1 mm; 1.8 µm; at a constant temperature of 40 ◦C) with UV detection
(Photodiode array (PDA) detector set at 259 nm) was used for the simultaneous quantification of the
urinary metabolites [38]. Retained compounds were eluted with 4 mL HAc solution (10%, v:v). Levels
of metabolites were calculated based on the corresponding matrix-matched calibration curve.
2.3.4. Assessment of Endothelial Function, Carotid Intima Media Thickness, and Retinal
Microvascular Caliber
Vascular endothelial function was assessed via FMD of the right brachial artery, 3–4 cm proximal
to the elbow. FMD was measured in the supine position with a mobile Esaote MyLabTM Five portable
ultrasound device (Genoa, Italy) with an Esaote Doppler probe (LA523, 12 MHz) connected to
computerized software with edge detection technology (Quipu Cardiovascular Suite™; Pisa, Italy)
as previously described [24,39]. Briefly, the computerized software determined the mean baseline
brachial artery lumen diameter (mm) over a 60-second period, followed by a 5-minute ischaemic
occlusion (inflation of a manual blood pressure cuff on the forearm to 50 mmHg supra-systolic
pressure). Following the 5-minute ischaemic occlusion, deflating the blood pressure cuff triggered
reactive hyperaemia and the maximum brachial artery lumen diameter (µm) was recorded during
this period. The maximum lumen diameter displacement during reactive hyperaemia from the mean
baseline measurements was expressed as the percentage of the mean baseline brachial lumen diameter
(% FMD).
The cIMTs of the left and right carotid arteries were determined by B-mode ultrasonography as
previously described [40,41]. cIMT measurements were performed in the supine position with the
head tilted in a 45◦ angle upwards. The diameter of carotid intima was determined using an Esaote
MyLabTM Five portable ultrasound device (Genova, Italy) and a B-linear-mode Esaote Doppler probe
(LA523, 12 MHz, Genoa, Italy) connected to computerized software (RF-QIMT software, Genova, Italy)
specific for the determination of carotid metrics. Measurements were taken 5 mm proximal to the
dilation of the carotid bulb. The mean of the left and right carotid diameter and mean of the left and
right cIMT were calculated and used for statistical analysis.
Additionally, retinal images were captured with a Canon CR2 digital camera (Canon Europa
NV, The Netherlands) and analyzed with semi-automated software (MONA REVA 2.1.1 developed
at VITO; https://mona.health) by trained investigators using a standardized protocol as previously
described [24]. Briefly, the central retinal arteriolar equivalent (CRAE) of the 6 largest arterioles and the
central retinal venular equivalent (CRVE) of the 6 largest venules were determined in the area between
0.5 and 1 disc diameter from the optic disc margin and also expressed as a CRAE/CRVE ratio (AVR).
The calculations of the vessel metrics were based on the revised Parr-Hubbard formulas as reported
previously [42].
2.4. Statistical Analysis
All statistical analyses were performed with IBM® SPSS® software (version 25; New York, NY,
USA). Depending on data distribution, a paired sample Student’s t-test (parametric) or Wilcoxon
signed-rank test (non-parametric) was used to identify significant differences between baseline and
follow-up visits. A Spearman’s Rho correlation (nonparametric data) was used to identify correlations
between variables. To determine the association between NO2 or individual BTEX compounds or total
BTEX (a summation of all individual BTEX compounds for each participant as a proxy for combined
effect of BTEX) and different cardiovascular outcomes, a linear mixed model (LMM) regression analysis
was used with participants nested in each visit. Variables with skewed data distribution (BTEX
and total BTEX) were log-transformed for regression analysis. To evaluate personal air pollution
effects on cardiovascular outcomes independent of potential confounding effects, we selected a priori
covariates that are known determinants for cardiovascular outcomes and variables with a potential
link with personal air pollution exposure and cardiovascular outcomes. These include age, BMI,
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smoking, socio-economic status (reflected by employment), sleep, and ambient temperature [43–47].
For estimated effects on SBP and DBP, the statistical model included NO2 or BTEX or total BTEX
as an exposure variable, participants at each time point as a random effects factor variable with
random intercept to account for possible inter-individual variation while adjusting for age, BMI, date of
assessment visit, and average temperature as continuous fixed effects and smoking status, employment
status, and hours of sleep at night as fixed categorical variables. For effects on other vascular outcomes,
we additionally adjusted LMMs for SBP. To determine estimated effects on % FMD and cIMT, the mean
brachial diameter and carotid diameter were additionally adjusted for, respectively. Q-Q plots of the
residuals were used to test the assumptions of linearity. The significance threshold was set at p < 0.05
for all statistical analysis.
3. Results
3.1. Baseline Population Characteristics
A total number of 77 female participants were recruited for the study. Sixteen participants who
completed their baseline visits did not consent to continue with the 6-month follow-up visit and were
excluded from the study. A total number of 61 healthy female participants (mean ± SD age at baseline:
42.5 ± 13.4 years) of mixed ancestry completed both assessment visits (Table 1).
The majority of participants were current smokers (69%; smoking frequency, <20 cigarettes/day),
but none reported any history of heart or other current serious health problems. Participants were mostly
unemployed (49%). Most participants were overweight with a mean ± SD BMI of 27.7 ± 8.4 kg/m2.
Most participants (n = 37; 61%) reported that they sleep 6 to 9 hours per night. The mean ± SD SBP and
DBP values (SBP: 122.5 ± 19.9) mmHg, and DBP: 84.2 ± 12.0 mmHg) were within the normal range
(Table 2). In total, 11 participants (18%) presented with hypertension (either SBP of ≥140 mmHg or
DBP of ≥90 mmHg) at baseline. The median hsCRP level was above the 3 mg/L cut-off value, and the
majority of participants (n = 35; 61%) exhibited elevated hsCRP levels.
Table 1. Baseline study population characteristics (n = 61).
Variable Baseline
Age (years) 42.5 ± 13.4
Smoking status
Current smoker (n) 42 (69%)
Employment
Unemployed (n) 30 (49%)
Part-time (n) 25 (41%)
Full-time (n) 6 (10%)
Hours of sleep per night
<3 h (n) 1 (2%)
3 to ≤6 h (n) 7 (12%)
6 to ≤9 h (n) 37 (61%)
>9 h (n) 16 (25%)
BMI, kg/m3 (n) 27.7 ± 8.4
High-sensitivity C-reactive protein (mg/L) a, b 6.3 (0.2 to 37.1)
Elevated hsCRP (>3 mg/L)
Yes (n) 35 (61%)
No (n) 22 (39%)
Urine creatinine (mmol/L) 13.5 ± 7.1
Data presented as mean ± SD or n (%); a data presented as median (range); b sample size: n = 57.
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Table 2. Baseline cardiovascular parameters (n = 61).
Variable Baseline
Blood pressure
Systolic blood pressure (SBP); mmHg) 122.5 ± 19.9
Diastolic blood pressure (DBP; mmHg) 84.15 ± 12.0
Hypertension
(Either SBP of >140 mmHg or DBP of >90 mmHg)
Yes, n 15 (25%)
No, n 46 (75%)
Flow-mediated vasodilatation a
Brachial diameter (mm) 3.22 ± 0.69
% Flow-mediated Dilatation (% FMD) b 5.21 (−7.93 to 23.50)
Retinal caliber c
Central retinal arteriolar equivalent (CRAE; µm) 157.9 ± 16.4
Central retinal venular equivalent (CRVE; µm) 238.4 ± 20.1
CRAE/CRVE ratio (AVR) 0.66 ± 0.06
Carotid artery
Carotid diameter (mm) 7.16 ± 0.84
Carotid intima media thickness (cIMT; µm) 657.2 ± 159.3
Data presented as mean ± SD or n (%); a sample size: n = 60; b data presented as median (range); c sample size:
n = 58.
3.2. Personal Ambient Exposure Variable Outcomes and Urinary Metabolites
The mean NO2 and median benzene, ethyl-benzene, m+p-xylene, and o-xylene levels were
significantly higher at the baseline visit compared to at the follow-up visit (Table 3). Personal toluene
exposure accounted for ~50% of the total BTEX exposure level at baseline and follow-up visits, while
benzene exposure was the lowest at both baseline and follow-up visits. The mean temperature did not
differ between baseline and follow-up (Table 3). Strong positive correlations were observed between
all personal exposure concentrations (p < 0.001) (Table A1). No significant differences in urinary
metabolites were observed between baseline and follow-up visits.
Table 3. Air pollution characteristics at baseline and 6-month follow-up (n = 61).
Variable Baseline Follow-Up
Temperature a, b (◦C) 21.6 ± 3.2 21.9 ± 2.7
Personal air pollution measurements
NO2 a, c (µg/m3) 13.6 ± 4.8 10.6 ± 4.7 **
Total BTEX c, d (µg/m3) 43.0 (12.0 to 327.7) 34.31 (7.1 to 405.1)
Benzene c (µg/m3) 3.9 (0.7 to 14.2) 2.2 (0.5 to 9.3) *
Toluene c (µg/m3) 22.1 (5.6 to 189.2) 18.0 (3.7 to 284.1)
Ethyl-benzene c (µg/m3) 2.8 (1.1 to 34.4) 2.3 (0.7 to 21.4) *
m+p-xylene c (µg/m3) 9.2 (3.4 to 117.4) 7.5 (2.0 to 74.8) *
o-xylene c (µg/m3) 3.2 (1.2 to 43.8) 2.7 (0.7 to 24.7) *
Urinary metabolites e
HPMA f (ng/mL) 1686 (92 to 12,793) 1812 (120 to 12,613)
PMA g (ng/mL) 0.05 (0.05 to 0.34) 0.05 (0.05 to 0.34)
MU h (ng/mL) 62.5 (62.5 to 498.0) 62.5 (62.5 to 595.0)
BMA i (ng/mL) 14.7 (2.5 to 588.0) 14.3 (2.5 to 699.0)
3+4MHA j (ng/mL) 1061 (31.8 to 9512.0) 845 (50.0 to 32,078.0)
Data presented as median (range) or a mean ± SD; b the mean represents the average 7-day recorded temperatures
(30-minute interval temperature recordings) for each participant prior to the assessment visit, n = 60. c Values reflect
the mean 7-day average during the 7-day period prior to the assessment visit, n = 56 to 61. d Values represent
the mean values of the sum of individual BTEX measurements for each participant as a proxy for total BTEX
exposure. e Values of samples below limit of detection (LOD) were replaced by LOD/2. f Samples concentrations
above LOD (>80 ng/mL; baseline/follow-up: n = 61/61). g Samples concentrations above LOD (>0.09 ng/mL;
baseline/follow-up: n = 10/6). h Samples concentrations above LOD (>125 ng/mL; baseline/follow-up: n = 14/20).
i Samples concentrations above LOD (>5 ng/mL; baseline/follow-up: n = 46/45). j samples concentrations above
LOD (>100 ng/mL; baseline/follow-up: n = 60/58). * p < 0.05; ** p < 0.01.
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3.3. Air Pollution Exposure and Cardiovascular Endpoints
NO2 exposure was positively associated with blood pressure and negatively associated with
blood vessel diameters. Each SD increment (4.96 µg/m3) in NO2 was associated with 2.42 mmHg
(95% CI: 0.03 to 4.80 mmHg; p = 0.047) and 1.76 mmHg (95% CI: 0.00 to 3.52 mmHg; p = 0.050) increase
in SBP and DBP, respectively (Table 4). Each NO2 SD increment was associated with −2.08 µm (95% CI:
−4.13 to −0.02 µm; p = 0.048) decrease in CRVE and −0.11 mm (95% CI: −0.19 to −0.03 mm; p < 0.010)
decrease in mean baseline brachial diameter.
Table 4. Estimated effects of personal NO2 and total BTEX on vascular outcomes.
Variable Exposure Variable Estimate a,b (95% CI) p-Values
SBP c (mmHg) NO2 2.42 (0.03; 4.80) 0.047
Total BTEX 1.54 (−1.38; 4.46) 0.297
DBP c (mmHg) NO2 1.76 (0.00; 3.52) 0.050
Total BTEX 2.07 (0.06; 4.07) 0.043
CRAE d (µm) NO2 −0.47 (−2.25; 1.31) 0.599
Total BTEX −0.70 (−2.88; 1.47) 0.521
CRVE d (µm) NO2 −2.08 (−4.14; −0.02) 0.048
Total BTEX −0.29 (−3.00; 2.39) 0.829
Mean brachial diameter d (mm) NO2 −0.11 (−0.19; −0.03) 0.005
Total BTEX −0.08 (−0.17; 0.01) 0.090
% FMD e NO2 −0.11 (−1.00; 0.77) 0.801
Total BTEX 0.30 (−0.56; 1.15) 0.492
Carotid Diameter d (mm) NO2 −0.06 (−0.19; 0.08) 0.393
Total BTEX −0.12 (−0.26; 0.02) 0.082
cIMT f (µm) NO2 1.23 (−23.63; 26.09) 0.921
Total BTEX 12.76 (−10.55; 36.06) 0.275
a All models adjusted for date of assessment visit, average temperature, age, body-mass index (BMI), smoking, and
employment status (random factor: participant). b Estimates expressed as a difference in cardiovascular endpoint
for each SD increment in exposure. c Additionally adjusted for hours of sleep at night. d Additionally adjusted
for SBP. e Additionally adjusted for SBP and mean brachial diameter. f Additionally adjusted for the SBP and
carotid diameter.
BTEX exposure was positively associated with blood pressure and cIMT measurements. Each SD
increments in total BTEX (2.56 µg/m3) and o-xylene (2.51 µg/m3) were associated with a 2.07 mmHg
(95% CI: 0.06 to 4.07 mmHg; p = 0.043) and 2.00 mmHg (95% CI: 0.21 to 3.80 mmHg; p = 0.029) increase
in DBP, respectively (Table 4; and Table A2). Each SD (2.08 µg/m3) increment increase in benzene was
positively associated with 24.88 µm (95% CI: 2.19 to 47.57 µm); p = 0.032) increase in cIMT (Table A5).
The urinary metabolite 3+4MHA was negatively associated with vascular function as indicated
by % FMD with an estimated effect of −1.45% (95% CI: −2.38% to −0.51%; p = 0.003) for each SD
(3.12 ng/mL) increment in 3+4MHA (Table A4). For more detailed results on effects of exposure on
vascular outcomes, refer to Tables A2–A5.
4. Discussion
The current study set out to determine personal air pollution exposure levels as measured by NO2
and BTEX, in a panel study of female adults residing in the Cape Town region of South Africa, and
investigated whether these exposure levels are associated with markers of cardiovascular risk. Major
findings of the study are: (1) compared to international air quality standards, our participants’ personal
exposure to NO2 and BTEX was relatively low, and (2) despite the relatively low exposure levels, we
could demonstrate associations between air pollutants and several cardiovascular parameters: SBP
and DBP (NO2 and BTEX), baseline brachial artery diameter (NO2), CRVE (NO2), and cIMT (benzene).
The mean 7-day personal NO2 exposure concentrations (Table 3) observed during the course of
the study (range: 2.94 µg/m3–25.35 µg/m3) remained below the recommended WHO, European Union
(EU) and South African air quality standards for NO2: annual exposure of <40 µg/m3 and 1-hour
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exposure of <200 µg/m3 [48–51]. At baseline, 24 (22%) of the individual mean benzene measurements
(range: 0.475 µg/m3–14.17 µg/m3) were higher than WHO and EU annual recommended standards
(<5 µg/m3), although the median values were below the standards [17,48].
Furthermore, the mean NO2 and median benzene concentrations at baseline in our study
population (NO2: 13.6 ± 4.8 µg/m3 and benzene: 3.22 (0.77–14.17) µg/m3) were within the lower range
of annual mean ambient NO2 and benzene concentrations of major European cities, with NO2 ranging
from 8 µg/m3 in Stockholm to 43 µg/m3 in Barcelona, and benzene ranging between 2 and 12 µg/m3
across various cities [3,52–54].
Compared to other studies from the Western Cape Province, the observed mean personal NO2
levels in our study were comparable with recently reported annual mean NO2 levels from air quality
monitoring stations in neighboring areas (Goodwood: 21 µg/m3; Plattekloof: 10 µg/m3) [49]. The
personal NO2 and individual BTEX concentrations in the current study were furthermore similar to
those measured previously (2011–2014) in the Drakenstein sub-district, ~60 km from the City of Cape
Town [55]. In this study, household NO2 and BTEX levels (reported as 2-week median values) were
measured in more than 500 homes of families of African and mixed ancestry (NO2: 7.9 (Interquartile
range (IQR): 3.8–13.3) µg/m3, benzene: 5.6 (IQR: 2.6–17.1) µg/m3, toluene: 19.8 (IQR: 9.3–53.2) µg/m3,
ethyl-benzene: 2.1 (IQR: 0.9–53.2) µg/m3, m+p-xylene: 5.8 (2.4–16.2) µg/m3, and o-xylene 2.4 (IQR:
1.1–7.0) µg/m3).
Ambient outdoor BTEX levels are infrequently measured in the Western Cape Province of South
Africa. The Provincial Government Report (2013) reported on BTEX levels (measured with passive
samplers) from only two locations in one rural town (Riversdale) in the province [49]. The reported
values from Riversdale (two locations with benzene concentrations of 0.89 and 1.05 µg/m3, respectively,
toluene concentrations of 2.66 and 1.04 µg/m3, respectively, ethyl-benzene concentrations of 0.43 and
0.27 µg/m3, respectively, and xylene concentrations of 1.82 and 1.19 µg/m3, respectively,) were generally
lower than the personal BTEX exposure levels measured in our study [49].
Our results showed that personal NO2 and total BTEX (mostly driven by o-xylene) exposure
was positively associated with blood pressure outcomes after adjusting for covariates (Table 4). Both
long- and short-term exposure to ambient gaseous pollutants has previously been associated with
haemodynamic changes including blood pressure, even at low exposure concentrations [18,56–59].
Our findings support those of Chan et al. (2015) who examined the effects of NO2 and fine PM
(≤2.5 µm; PM2.5) in a female population and showed that a 10 ppb increase in NO2 was associated with
a higher pulse pressure (0.4 mmHg) [60]. In the same study, PM2.5 was also associated with higher SBP
(1.4 mmHg), pulse pressure (1.0 mmHg), and mean arterial pressure (0.8 mmHg) [60]. The authors
speculated that exposure-associated autonomic dysregulation of vascular tone may be a possible
underlying mechanism of their findings [60,61]. This may indeed be the case, as our results showed
negative associations between NO2 and vessel diameters as indicated by the baseline brachial artery
diameter and CRVE. The vasoconstrictive effects of both long-term low-concentrations and short-term
high-concentration exposure to ambient air pollution have previously been described [62,63]. In the
study by Brook et al. (2002), an inverse relationship with brachial artery diameter (ultrasonography)
was also demonstrated in 25 healthy adults, although at higher exposure concentrations (150 µg/m3 fine
PM and 120 ppb O3) and a shorter exposure period (2 hour) compared to our exposure concentrations
and exposure period [62]. The authors, in a finding similar to ours, failed to demonstrate ambient air
pollution exposure-associated effects on FMD [62].
Previous studies have investigated the possible mechanism involved in air pollution
exposure-associated vasoconstriction and suggested possible stimulation of the pulmonary vagal
afferent neurons and the subsequent increase in sympathetic nervous system reflex activity or
an upregulation (directly or via oxidative stress pathways) of vascular endothelin 1 and 3
(vasoconstrictors) [62,64]; however, more studies are required to elucidate the underlying mechanisms.
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Benzene exposure was associated with sub-clinical atherosclerotic changes as measured by
cIMT in our study with a relatively large estimated effect on cIMT. cIMT is considered a marker of
pro-atherosclerotic processes such as inflammation, a strong predictor of future cardiovascular events [65],
and increased cIMT has previously been implicated in long-term ambient PM exposure [19,66]. It has also
been suggested that women are at higher risk of increased PM-induced cIMT than men [19]. Short-term
air pollutant exposure levels in our study were not significantly associated with inflammation (as
measured by hsCRP), suggesting that other possible mechanisms may explain the pro-atherosclerotic
effects of benzene.
3+4MHA appeared to be a prominent urinary metabolite/tracer for exposure in our study as
it strongly correlated with all personal exposure levels (Table A1). 3+4MHA is a urinary marker
for toluene (80% inhaled toluene metabolized to BMA or MHA) and the primary metabolite for
xylene exposure (95% inhaled xylene metabolized to MHA post-exposure) [38,67–70]. Aside from
being a diesel exhaust derivative, xylene is also often used as a solvent in industrial and household
products (e.g., adhesives, coatings, degreasers, detergents, dyes, ink, paint, pesticides, polishes, and
solvents) [18,56–59].
Xylene is a carcinogen and also associated with central nervous system abnormities such as brain
and neurobehavioral morbidities [71,72]. In our study, the positive association between personal total
BTEX and DBP was mostly driven by o-xylene, while no adverse associations between BMA (marker of
toluene exposure) and vascular endpoints were observed. The significant association between o-xylene
and DBP, as well as between its primary urinary metabolite, 3+4MHA (Table A4), and endothelial
function suggests that o-xylene may significantly contribute to vascular dysfunction (increased DBP
and reduced endothelial function as measured by % FMD) in our study population. More focused
investigations on possible underlying mechanisms are required.
5. Strengths and Limitations
The results from the current study are presented with some strengths and limitations. Strengths
of current study include the measurement of personal exposure levels, as opposed to levels obtained
from centralized air quality monitoring stations in many previous studies from the SSA region.
Personal measurements are generally considered a more accurate representation of exposure levels.
An additional strength of the study is the fact that we used measurements of different cardiovascular
endpoints to investigate physiological effects. To the best of our knowledge, this study is the first
to explore the cardiovascular health effects of personal air pollution exposure, in combination with
urinary exposure markers, in the South African research setting.
Limitations of the study include a relatively small sample size representing only women, of whom
the majority were smokers. The male participant enrolment rate was low, mostly due to employment
obligations that resulted in difficulty to attend assessment visits. The high prevalence of smokers
in our cohort may be ascribed to the high smoking rates that have previously been reported in the
region [73,74]. The robust correction for the effects of smoking on various outcomes, based only on
smoking status, may not have been optimal. Using levels of biomarkers of smoking such as cotinine
may have been a more accurate adjustment for the smoking effect and would have also included
the effects of possible second-hand smoke. Personal exposure measurements with a 30 cm radius
extended in front of the face (within the breathing zone) and the inclusion of blank field samples
in the study would also have been more desirable. These factors should be considered in future
studies. Additionally, as previously shown, the effects of air pollution vary across sex, ethnicity,
and health status [75–77]. Our results represent only the exposure effects in an apparently healthy,
female population of mixed ancestry and care should be taken to not extrapolate our findings to the
general population.
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6. Conclusions
Our results show that personal ambient air pollution exposure in women residing in Cape
Town, even at relatively low levels, is associated with markers of cardiovascular risk including blood
pressure (SBP and DBP), vascular tone/diameter (baseline brachial artery diameter and CRVE), vascular
endothelial function (% FMD), and subclinical atherosclerosis (cIMT).
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Figure A1. Photos of samplers used for personal exposure measurements: (a) Gradko rapid air NO2 
sampler (product: DIFRAM-100; UKAS method: GLM 7; detection limit: <0.2 μg/m3 for 1-week 
exposure); (b) activated Gradko rapid air NO2 sampler; (c) RadielloTM diffusive cartridge (right) and 
diffusive body attached to a triangular support plate (left) (products: Rad130, RAD120, and RAD121; 
detection limit for BTEX: 0.05, 0.01, 0.01, and 0.01 μg/m3, respectively; calibration: CS2); (d) ACR 
Systems Inc. temperature logger (product: SmartButton (01-0187); detection limit: −40 °C to 85 °C); (e) 
Figure A1. Photos of samplers used for personal exposure measurements: (a) Gradko rapid air NO2
sampler (product: DIFRAM-100; UKAS method: GLM 7; detection limit: <0.2 µg/m3 for 1-week
exposure); (b) activated Gradko rapid air NO2 sampler; (c) RadielloT diffusive cartridge (right) and
diffusive body attached to a triangular support plate (left) (products: Rad130, RAD120, and RAD121;
detection li it for BTEX: 0.05, 0.01, 0.01, and 0.01 µg/m3, respectively; calibration: CS2); (d) ACR
Syste s Inc. te perature logger (product: SmartButton (01-0187); detection limit: −40 ◦C to 85 ◦C);
(e) air monitoring devices in the mesh pocket of a backpack (product: Barron BB0110 Curve and Arch
Design backpacks); (f) backpack worn by participants with samplers located 50 to 60 cm from the face.
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Table A1. Spearman’s Rho correlations coefficients (r) for all personal measures of exposure and
urinary metabolites.
NO2 Benzene Toluene Ethyl-benzene m+p-xylene o-xylene
Personal Exposure a
Benzene 0.616 ***
Toluene 0.452 *** 0.461 ***
Ethyl-benzene 0.622 *** 0.585 *** 0.652 ***
m+p-xylene 0.642 *** 0.595 *** 0.658 *** 0.983 ***
o-xylene 0.643 *** 0.589 *** 0.667 *** 0.972 *** 0.989 ***
Total BTEX b 0.524 *** 0.474 *** 0.951 *** 0.790 *** 0.798 *** 0.808 ***
Urinary metabolites c
HPMA 0.081 0.186 * −0.020 −0.002 0.023 0.017
PMA 0.117 0.011 −0.218 * −0.112 −0.105 −0.123
MU 0.061 0.152 −0.009 −0.749 −0.038 −0.024
BMA −0.051 −0.070 0.120 −0.023 −0.018 −0.005
3+4MHA 0.273 ** 0.341 *** 0.218 * 0.192 * 0.215 * 0.210 *
a n = 111 to 113; b values represent the mean values of the sum of individual BTEX measurements for each participant;
c n = 111 to 121; * p < 0.05; ** p < 0.01; *** p < 0.001.
Table A2. Estimated effects of personal NO2, total BTEX, BTEX, and 3+4MHA urinary metabolite on
SBP and DBP.
Variable Exposure Variable Estimate a,b (95% CI) p-Values
SBP c (mmHg) NO2 2.42 (0.03; 4.80) 0.047
Total BTEX 1.54 (−1.38; 4.46) 0.297
Benzene 2.51 (−0.21; 5.22) 0.070
Toluene 0.92 (−2.04; 3.88) 0.539
Ethyl-benzene 1.44 (−1.15; 4.03) 0.272
m+p-xylene 1.62 (−1.01; 4.25) 0.224
o-Xylene 2.12 (−0.50; 4.74) 0.112
Urinary metabolite d
3+4MHA −0.52 (−3.10; 2.05) 0.687
DBP c (mmHg) NO2 1.76 (0.00; 3.52) 0.050
Total BTEX 2.07 (0.06; 4.07) 0.043
Benzene 1.19 (−0.73; 3.10) 0.220
Toluene 1.77 (−0.25; 3.80) 0.086
Ethyl-benzene 1.58 (−0.20; 3.36) 0.080
m+p-xylene 1.72 (−0.09; 3.53) 0.062
o-xylene 2.01 (0.21; 3.80) 0.029
Urinary metabolite d
3+4MHA −0.40 (−2.28; 1.48) 0.673
a All models adjusted for date of assessment visit, average temperature, age, BMI, smoking, and employment status
(random factor: participant). b Estimates expressed as a difference in cardiovascular endpoint for each SD increment
in exposure. c Additionally adjusted for hours of sleep at night. d Additionally adjusted for hours of sleep at night
and urine creatinine.
Table A3. Estimated effects of personal NO2, total BTEX, BTEX, and 3+4MHA urinary metabolite on
CRAE and CRVE.
Variable Exposure Variable Estimate a,b (95% CI) p-Values
CRAE c (µm) NO2 −0.47 (−2.25; 1.31) 0.599
Total BTEX −0.70 (−2.88; 1.47) 0.521
Benzene −0.54 (−2.51; 1.42) 0.582
Toluene −0.74 (−2.90; 1.43) 0.500
Ethyl-benzene −0.49 (−2.24; 1.26) 0.579
m+p-xylene −0.60 (−2.40; 1.21) 0.511
o-xylene −0.68 (−2.53; 1.16) 0.461
Urinary metabolite d
3+4MHA −0.57 (−2.297; 1.167) 0.517
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Table A3. Cont.
Variable Exposure Variable Estimate a,b (95% CI) p-Values
CRVE c (µm) NO2 −2.08 (−4.14; −0.02) 0.048
Total BTEX −0.29 (−3.00; 2.39) 0.829
Benzene −0.67 (−3.11; 1.78) 0.588
Toluene −0.40 (−3.11; 2.31) 0.768
Ethyl-benzene −0.53 (−2.64; 1.58) 0.616
m+p-xylene −0.50 (−2.62; 1.62) 0.638
o-xylene −0.61 (−2.85; 1.63) 0.587
Urinary metabolite d
3+4MHA −0.14 (−2.19; 1.91) 0.890
a All models adjusted for date of assessment visit, age, BMI, average temperature, smoking, and employment status
(random factor: participant). b Estimates expressed as a difference in cardiovascular endpoint for each SD increment
in exposure. c Additionally adjusted for SBP. d Additionally adjusted for SBP and urine creatinine.
Table A4. Estimated effects of personal NO2, total BTEX, BTEX, and 3+4MHA urinary metabolite on
FMD measurements.
Variable Exposure Variable Estimate a,b (95% CI) p-Values
Mean brachial
diameter c (mm) NO2 −0.11 (−0.19; −0.03) 0.005
Total BTEX −0.08 (−0.17; 0.01) 0.090
Benzene −0.01 (−0.10; 0.08) 0.760
Toluene −0.09 (−0.17; 0.01) 0.065
Ethyl-benzene −0.08 (−0.17; 0.00) 0.057
m+p-xylene −0.06 (−0.15; 0.02) 0.144
o-xylene −0.06 (−0.15; 0.03) 0.189
Urinary metabolite d
3+4MHA 0.02 (−0.07; 0.11) 0.647
% FMD e NO2 −0.11 (−1.00; 0.77) 0.801
Total BTEX 0.30 (−0.56; 1.15) 0.492
Benzene −0.01 (−0.87; 0.85) 0.982
Toluene 0.36 (−0.50; 1.22) 0.403
Ethyl-benzene 0.35 (−0.76; 0.90) 0.870
m+p-xylene 0.07 (−0.77; 0.92) 0.862
o-xylene 0.16 (−0.68; 1.00) 0.705
Urinary metabolite f
3+4MHA −1.45 (−2.38; −0.51) 0.003
a All models adjusted for date of assessment visit, age, BMI, average temperature, smoking, and employment status
(random factor: participant). b Estimates expressed as a difference in cardiovascular endpoint for each SD increment
in exposure. c Additionally adjusted for SBP. d Additionally adjusted for SBP and urine creatinine. e Additionally
adjusted for SBP and baseline brachial diameter. f Additionally adjusted for the SBP, baseline brachial diameter, and
urine creatinine.
Table A5. Estimated effects of personal NO2, total BTEX, BTEX, and 3+4MHA urinary metabolite on
carotid artery measurements.
Variable Exposure Variable Estimate a,b (95% CI) p-Values
Carotid diameter c
(mm) NO2 −0.06 (−0.19; 0.08) 0.393
Total BTEX −0.12 (−0.26; 0.02) 0.082
Benzene −0.07 (−0.20; 0.07) 0.331
Toluene −0.11 (−0.25; 0.03) 0.132
Ethyl-benzene −0.10 (−0.22; 0.02) 0.097
m+p-xylene −0.10 (−0.23; 0.02) 0.109
o-xylene −0.09 (−0.22; 0.04) 0.156
Urinary metabolite d
3+4MHA −0.07 (−0.20; 0.07) 0.325
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Table A5. Cont.
Variable Exposure Variable Estimate a,b (95% CI) p-Values
cIMT e (µm) NO2 1.23 (−23.63; 26.09) 0.921
Total BTEX 12.76 (−10.55; 36.06) 0.275
Benzene 24.88 (2.19; 47.57) 0.032
Toluene 9.37 (−13.24; 31.99) 0.407
Ethyl-benzene 9.10 (−14.32; 32.52) 0.437
m+p-xylene 8.64 (−15.36; 32.64) 0.471
o-xylene 13.06 (−10.74; 36.85) 0.274
Urinary metabolite f
3+4MHA −10.56 (−30.75; 9.63) 0.302
a All models adjusted for date of assessment visit, age, BMI, average temperature, smoking, and employment status
(random factor: participant). b Estimates expressed as a difference in cardiovascular endpoint for each SD increment
in exposure. c Additionally adjusted for SBP. d Additionally adjusted for SBP and urinary creatinine. e Additionally
adjusted for SBP and mean brachial diameter. f Additionally adjusted for the SBP, mean carotid diameter, and
urinary creatinine.
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